The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Clinical research

Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study

EuroIntervention 2012;8:486-492 published online ahead of print June 2012. DOI: 10.4244/EIJV8I4A76

1. University of Caen, Caen, France; 2. Duke Clinical Research Institute, Durham, NC, USA; 3. INSERM U-698, AP-HP and Université Paris 7, Paris, France; 4. Institute of Cardiology, University of Ferrara, Ferrara, Italy; 5. Radboud Unive

Aims: Fondaparinux is an indirect, Factor Xa inhibitor that requires co-administration of another anticoagulant with anti-Factor IIa activity for percutaneous coronary intervention (

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Vasomotor function and re-endothelialisation after implantation of biodegradable abluminal polymer coated paclitaxel-eluting stents in rabbit iliac arteries: a time-course study